Zoetis Inc. (NYSE:ZTS) Shares Acquired by Mattern Capital Management LLC

Mattern Capital Management LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 7.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 51,843 shares of the company’s stock after buying an additional 3,576 shares during the quarter. Mattern Capital Management LLC’s holdings in Zoetis were worth $8,447,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Pensionfund Sabic lifted its holdings in shares of Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after buying an additional 4,000 shares during the period. PFW Advisors LLC purchased a new position in Zoetis in the 4th quarter valued at approximately $1,764,000. Callahan Advisors LLC increased its stake in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after purchasing an additional 6,221 shares in the last quarter. CIBC Asset Management Inc increased its stake in Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after purchasing an additional 46,050 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after purchasing an additional 279,092 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms recently weighed in on ZTS. Leerink Partners began coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Piper Sandler dropped their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Morgan Stanley dropped their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, UBS Group began coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $214.90.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $157.38 on Friday. The company has a market cap of $70.47 billion, a P/E ratio of 28.77, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The business has a fifty day simple moving average of $166.86 and a 200-day simple moving average of $178.14.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.27%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is currently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.